WORLD CHILD CANCER

Archived: Novartis: Sandoz Expands Partnership with World Child Cancer

Sandoz, a division of the Novartis Group, has announced the expansion of a pilot project with leading charity World Child Cancer, aimed at improving access to treatment and optimizing survival outcomes for children suffering from cancer in four developing countries.


Jon Rosser, Chief Executive of World Child Cancer, said: “It is just unacceptable that children’s odds of surviving cancer depend so much on geography. In developed countries, 80 percent now survive, but in developing countries it’s still only about 10 percent. World Child Cancer is changing this – in our programs we can raise that survival rate to around 60 percent.”

He added: “We are very excited at this growing partnership with Sandoz, which will enable us to prevent so many children dying without even a diagnosis and without effective pain relief. We believe that all children, regardless of where they live, deserve better.”

The agreement builds on an existing partnership with World Child Cancer in the Philippines, where Sandoz is funding staff training needs and helping children to access diagnosis and subsequent treatment. It expands the partnership to cover three additional countries across three continents: Ghana, Mexico and Myanmar.

These particular projects were chosen because of the gravity of the situation in the four regions concerned: across all four, an estimated 6000 children develop cancer each year, but only approximately 20 percent even receive a diagnosis, let alone effective treatment.

Peter Stenico, Sandoz Head of Oncology, said: “These projects will take simple, pragmatic measures to attack cancer where it is most vulnerable: among children suffering from forms of cancer that are often absolutely treatable. Together with World Child Cancer, we believe we can make a real difference by enhancing the standard of care for children in these countries and, ultimately, improving childhood cancer survival rates.”

The expanded partnership highlights Sandoz’s commitment to work together with key stakeholders worldwide to expand access to healthcare. As a targeted philanthropy project, the work with World Child Cancer complements the broader Novartis Corporate Responsibility efforts across a number of lower-income countries.

Sandoz is a global leader in generic pharmaceuticals and biosimilars.

Latest News

Southern Company Builds on Transparency of Corporate Responsibility and Sustainability Efforts

Originally published at southerncompany.mediaroom.com. Southern Company ranked No. 19 on The DiversityInc Top 50 Companies for Diversity list in 2022.   Consistent with its commitment to transparency and stakeholder engagement, Southern Company has published its 2021 Corporate Responsibility Executive Summary, refreshed key environmental, social and governance (ESG) data and published…

A Sysco truck with a branded message makes it way through traffic.

Sysco Shares Its First Diversity, Equity and Inclusion Report

Originally published at investors.sysco.com.    Sysco Corporation, the leading global foodservice distribution company, announced the launch of its 2022 Sustainability Report and the company’s first Diversity, Equity and Inclusion (DEI) Report. “Sustainability is an integral part of our business strategy, called the Recipe For Growth, to ensure we are growing responsibly and…

Toyota Recognizes Everyday Heroes at the espnW Summit

Originally published at pressroom.toyota.com. Toyota Motor North America ranked No. 4 on The DiversityInc Top 50 Companies for Diversity list in 2022.    The espnW: Women + Sports Summit in Ojai, California, presented by Toyota, Toyota and espnW announced the seventh class of Toyota Everyday Heroes. Toyota’s Everyday Heroes program…